Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical cancer treatments developer Kinex Pharmaceuticals has selected an experimental compound, KX2-377, as a lead drug candidate for clinical development.
Subscribe to our email newsletter
The compound, which was discovered using Kinex Pharmaceuticals’ proprietary technology platform, is a potent, orally-available, and highly selective small molecule that inhibits tumor growth and metastasis. It works by inhibiting Src kinase phosphorylation, and is unique in that it was designed to target the substrate pocket of Src kinase instead of the ATP pocket.
“This compound-KX2-377-has demonstrated an excellent pharmacokinetic profile. We have encountered no safety problems thus far, and its unique properties provide opportunities for both anticancer treatment and maintenance therapy,” said Dr Allen Barnett, CEO of Kinex Pharmaceuticals.
The company is preparing for an investigational new drug (IND) application and planning for an FDA submission during the second quarter of 2006.